FDA Approvals in Prostate and Endometrial Cancers

In this week's episode, we are discussing two recent FDA approvals—one for prostate cancer, and the other for endometrial cancer. The radioconjugate lutetium Lu-177 vipivotide tetraxetan was approved for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Pembrolizumab was approved as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability–high or mismatch repair–deficient as determined by an FDA-approved test; eligible patients have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Radioligand for Metastatic Castration-Resistant Prostate Cancer

FDA Approves Pembrolizumab for Advanced Endometrial Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.